Literature DB >> 15289843

Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis.

Kiyoshi Kamada1, Yukishige Yamada, Tomoko Hirao, Heisuke Fujimoto, Yasushi Takahama, Masatoh Ueno, Tomoyoshi Takayama, Akihiko Naito, Shuya Hirao, Yoshiyuki Nakajima.   

Abstract

Aurora-A encodes a cell cycle regulated serine/threonine kinase that has essential functions for centrosome maturation and chromosome segregation. Aurora-A is amplified and overexpressed in various human carcinomas and is suggested to be a potential oncogene. To clarify the potential role of Aurora-A in human gastric carcinoma, we examined the amplification and expression in both tumor cell lines and primary carcinoma. We examined the amplification and overexpression of Aurora-A in 9 gastric carcinoma cell lines and 88 primary gastric carcinomas using Southern and Northern blot analysis, and confirmed a protein expression by immunohistochemical staining. We also investigated the relationship between Aurora-A overexpression and clinicopathological features of the tumors. Aurora-A amplification and overexpression was observed in 29% and 44.4% of cell lines and 12.5% and 41% of primary carcinomas, respectively. There was discordance between gene amplification and transcript expression, since in a previous study DNA amplification was the main mechanism for Aurora-A activation. Aurora-A overexpression exhibited significant association with increasing age and differentiated type gastric carcinoma. It was also detected in early stage gastric cancer as well as in gastric intestinal metaplasia, which is considered as a common precursor lesion for the differentiated type gastric carcinoma, and severe dysplastic cells showed stronger protein expression. We concluded that Aurora-A overexpression may well be involved in differentiated type gastric carcinogenesis. Further evaluation of the possible roles of Aurora-A and the regulation of Aurora-A expression in malignant cells will be critically important for the development of new strategies aimed at controlling the growth of malignant cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289843

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  33 in total

1.  Mantle cell lymphoma harboring Burkitt's-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities.

Authors:  Fábio Morato de Oliveira; Ana Paula Nunes Rodrigues-Alves; Antônio Roberto Lucena-Araújo; Ferdinando de Paula Silva; Fernanda Borges da Silva; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2014-03-29       Impact factor: 3.064

2.  Suppression of Aurora-A oncogenic potential by c-Myc downregulation.

Authors:  Shangbin Yang; Shun He; Xiaobo Zhou; Mei Liu; Hongxia Zhu; Yihua Wang; Wei Zhang; Shuang Yan; Lanping Quan; Jingfeng Bai; Ningzhi Xu
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

3.  Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.

Authors:  Ahmed Katsha; Lihong Wang; Janet Arras; Omar M Omar; Jeffrey Ecsedy; Abbes Belkhiri; Wael El-Rifai
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

4.  Differential expression of aurora-A kinase in T-cell lymphomas.

Authors:  Rashmi Kanagal-Shamanna; Norman L Lehman; James P O'Donnell; Megan S Lim; Daniel S Schultz; Dhananjay A Chitale; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Kedar V Inamdar
Journal:  Mod Pathol       Date:  2013-02-15       Impact factor: 7.842

5.  Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Authors:  Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin
Journal:  Invest New Drugs       Date:  2018-09-06       Impact factor: 3.850

6.  A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.

Authors:  James Foran; Farhad Ravandi; William Wierda; Guillermo Garcia-Manero; Srdan Verstovsek; Tapan Kadia; Jan Burger; Murray Yule; Gillian Langford; John Lyons; John Ayrton; Victoria Lock; Gautham Borthakur; Jorge Cortes; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-11-14

7.  Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression.

Authors:  Zhengyu Fang; Yi Xiong; Jiana Li; Li Liu; Manhui Li; Chao Zhang; Wei Zhang; Jun Wan
Journal:  Med Oncol       Date:  2010-06-29       Impact factor: 3.064

8.  Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.

Authors:  Ilana Chefetz; Jennie C Holmberg; Ayesha B Alvero; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

9.  Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.

Authors:  Altaf A Dar; Abbes Belkhiri; Jeffrey Ecsedy; Alexander Zaika; Wael El-Rifai
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 10.  Gastric cancer in the era of molecularly targeted agents: current drug development strategies.

Authors:  Hendrik-Tobias Arkenau
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.